Nuvation Bio Inc.
NYSE:NUVBBiotechnology
Healthcare
$3.81 +1.03%
+$0.06 today
- Market cap
- $1.34B
- Beta
- 1.56
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.42
52W Low $1.81High $9.75
Volume 9.92M
Average 4.07M
Income Statement
Follow revenue through to earnings.
Revenue
$62.90M
FY 2025 · Annual
+699.0% YoYOperating Income
-$213.06M
FY 2025 · Annual
Net Income
-$204.63M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7.87M | 62.9M |
| Cost of Revenue | 0 | 0 | 0 | 7.08M | 8.44M |
| Gross Profit | 0 | 0 | 0 | 795K | 54.46M |
| Gross Margin | — | — | — | 10.1% | 86.6% |
| Research & Development | 69.04M | 87.82M | 71.29M | 524.19M | 115.11M |
| Selling, General & Admin | 24.28M | 31.92M | 28.53M | 69.23M | 151.56M |
| Operating Expenses | 93.32M | 119.73M | 99.82M | 593.42M | 267.52M |
| Depreciation & Amortization | 184K | 199K | 222K | 683K | 1.74M |
| EBITDA | (86.66M) | (104M) | (75.58M) | (566.92M) | (189.21M) |
| EBITDA Margin | — | — | — | -7200.7% | -300.8% |
| Operating Income | (93.32M) | (119.73M) | (99.82M) | (592.63M) | (213.06M) |
| Operating Margin | — | — | — | -7527.3% | -338.7% |
| Interest Income | 2.96M | 7.45M | 24.61M | 27.06M | 21.43M |
| Interest Expense | 0 | 0 | 0 | 341K | 13.68M |
| Other Income / Expenses | 6.47M | 15.54M | 24.02M | 24.69M | 8.44M |
| Income Before Tax | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Pre-Tax Margin | — | — | — | -7213.8% | -325.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Net Margin | — | — | — | -7213.8% | -325.3% |
| EPS (Basic) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
| EPS (Diluted) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
| 197.89M | 216.72M | 218.88M | 268.77M | 341.54M | |
| 197.89M | 216.72M | 218.88M | 268.77M | 341.54M |
NUVB Earnings Waterfall · TTM
NYSE:NUVB · Revenue to Net Income
Key Ratios
EPS$-0.44
Gross Margin91.0%
Net Margin-176.1%
P/E Ratio8.8
P/S Ratio62.7
Analysis
$169.9M of revenue converted into -$149.8M of net income for the selected period. Gross margin is 91.0% and net margin is -176.1%, showing how much revenue survives after costs and taxes. EPS is $-0.44, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 21, 2026 | |
| 8-K | Current report | Aug 6, 2026 | |
| 10-Q | Quarterly report | Aug 6, 2026 |
How much revenue does NUVB generate?
Nuvation Bio Inc. (NUVB) reported $62.90M of revenue in fiscal 2025.
Is NUVB profitable?
Nuvation Bio Inc. (NUVB) reported -$204.63M of net income, with a net margin of -325.3%.
Continue the stock analysis
Jump to another research area for this company.